Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer sues over Accupril generic

Executive Summary

Newark, N.J. federal judge will hear arguments March 15 on Pfizer's request to preliminarily enjoin Teva and Ranbaxy from infringing an Accupril patent. Pfizer filed suit Jan. 28, alleging that the companies' generic quinapril infringes the patent. A court previously ruled that Teva's ANDA infringed, but Pfizer had not previously sued Ranbaxy. Teva began shipping quinapril manufactured under Ranbaxy's ANDA on Dec. 15 after Teva relinquished 180-day generic exclusivity rights (1"The Pink Sheet" Dec. 20, 2004, In Brief)...

Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts